Supernus Pharmaceuticals Inc. (SUPN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Supernus Pharmaceuticals Inc. (SUPN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How SUPN Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | 89.6% | -8.7% | -$38.6M | $46.0M | -4.4% |
| FY 2024 | $661.8M | 88.2% | 12.3% | $73.9M | $171.2M | 5.8% |
| FY 2023 | $607.5M | 44% | -0.9% | $1.3M | $83.7M | -0.5% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring SUPN)
- ✓Live walkthrough of SUPN's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
SUPN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SUPN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SUPN. Explore sector supply chains on /butterfly.
SUPN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Supernus Pharmaceuticals Inc. (SUPN)?
In FY 2025 (10-K), SUPN converted $719.0M of revenue into a 89.6% gross margin, 0% operating margin, and $46.0M in free cash flow (6.4% FCF margin).